Solventum Corporation (SOLV) EBITDA Margin: 30.62%
Is Solventum Corporation’s EBITDA margin high or low?
Solventum Corporation's EBITDA margin of 30.62% is 13% above its 5-year average of 27.07%, near the high end of its 5-year range (18.50%–30.62%).
As of Saturday, June 13, 2026. 24.67% above its 12-month average of 24.56%.
SOLV EBITDA Margin Chart
SOLV Average EBITDA Margin Chart
SOLV Current vs Average EBITDA Margin Chart
SOLV EBITDA Margin Metrics
EBITDA MARGIN
30.62%
EBITDA MARGIN AVG TTM
24.56%
EBITDA MARGIN AVG 3Y
26.05%
EBITDA MARGIN AVG 5Y
27.07%
EBITDA MARGIN AVG 10Y
27.07%
EBITDA MARGIN AVG 15Y
27.07%
EBITDA MARGIN AVG 20Y
27.07%
CURRENT VS TTM AVG
+24.67%
CURRENT VS 3Y AVG
+17.52%
CURRENT VS 5Y AVG
+13.11%
CURRENT VS 10Y AVG
+13.11%
CURRENT VS 15Y AVG
+13.11%
CURRENT VS 20Y AVG
+13.11%
SOLV Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Solventum Corporation (SOLV) | $13.66B | 30.62% | 24.56% | 26.05% | 27.07% |
| The Cooper Companies, Inc. (COO) | $13.24B | 25.74% | 26.63% | 26.11% | 26.16% |
| Align Technology, Inc. (ALGN) | $12.52B | 18.98% | 19.70% | 20.24% | 21.46% |
| Baxter International Inc. (BAX) | $10.77B | 6.81% | 8.65% | 4.13% | 9.00% |
| Walgreens Boots Alliance, Inc. (WBA) | $10.37B | -7.64% | -4.75% | -0.21% | 1.54% |
| Hologic, Inc. (HOLX) | $16.97B | 24.97% | 28.56% | 32.04% | 36.42% |
| Charles River Laboratories International, Inc. (CRL) | $9.03B | 10.23% | 12.29% | 18.59% | 20.64% |
| Tempus AI, Inc. (TEM) | $8.35B | -17.48% | -52.76% | -51.11% | -63.28% |
| Bio-Rad Laboratories, Inc. (BIO) | $7.73B | 48.39% | -17.53% | -54.94% | 28.49% |
| Moderna, Inc. (MRNA) | $19.80B | -131.33% | -118.72% | -58.16% | -40.65% |
Margin Comparison
Gross Margin
53.7%
EBITDA Margin
30.6%
Operating Margin
25.5%
Net Margin
17.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Solventum Corporation EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Solventum Corporation EBITDA Margin FAQ
- What is the EBITDA margin for Solventum Corporation (SOLV)?
- The EBITDA margin for SOLV stock is 30.62%.
- Is Solventum Corporation's EBITDA margin high or low?
- Solventum Corporation's EBITDA margin of 30.62% is 13% above its 5-year average of 27.07%, near the high end of its 5-year range (18.50%–30.62%).
- What is the TTM average EBITDA margin for Solventum Corporation (SOLV)?
- The TTM average EBITDA margin for SOLV stock is 24.56%.
- What is the 3Y average EBITDA margin for Solventum Corporation (SOLV)?
- The 3Y average EBITDA margin for SOLV stock is 26.05%.
- What is the 5Y average EBITDA margin for Solventum Corporation (SOLV)?
- The 5Y average EBITDA margin for SOLV stock is 27.07%.
- What is the 10Y average EBITDA margin for Solventum Corporation (SOLV)?
- The 10Y average EBITDA margin for SOLV stock is 27.07%.
- What is the 15Y average EBITDA margin for Solventum Corporation (SOLV)?
- The 15Y average EBITDA margin for SOLV stock is 27.07%.
- What is the 20Y average EBITDA margin for Solventum Corporation (SOLV)?
- The 20Y average EBITDA margin for SOLV stock is 27.07%.
Solventum Corporation EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | 30.62% |
| 2024-12-31 | 18.50% |
| 2023-12-31 | 27.18% |
| 2022-12-31 | 27.92% |
| 2021-12-31 | 30.34% |
| 2020-12-31 | 27.87% |
Related Metrics
About Solventum Corporation
Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- CEO
- Bryan C. Hanson